{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:25:44Z","timestamp":1792034744247,"version":"4.4.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C3\/20\/104"],"award-info":[{"award-number":["C3\/20\/104"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM144137"],"award-info":[{"award-number":["R35GM144137"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["I-1532"],"award-info":[{"award-number":["I-1532"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75741-y","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:34:09Z","timestamp":1784734449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preclinical characterization of a reversible XPO1 inhibitor for cancer therapy"],"prefix":"10.1038","volume":"17","author":[{"given":"Janne","family":"Van Hauwenhuyse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-7894","authenticated-orcid":false,"given":"Felien","family":"Reniers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7898-0868","authenticated-orcid":false,"given":"Leentje","family":"Persoons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Noppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6437-0129","authenticated-orcid":false,"given":"Casey E.","family":"Wing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0118-7483","authenticated-orcid":false,"given":"Ashley B.","family":"Niesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0502-1957","authenticated-orcid":false,"given":"Ho Yee Joyce","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Vanstreels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-4189","authenticated-orcid":false,"given":"Maarten","family":"Jacquemyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Boel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Vankerckhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yani","family":"Berckmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-5299","authenticated-orcid":false,"given":"Bert","family":"Kwanten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-4339","authenticated-orcid":false,"given":"An","family":"Coosemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Van den Mooter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-0726","authenticated-orcid":false,"given":"Yuh Min","family":"Chook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9597-0629","authenticated-orcid":false,"given":"Wim","family":"Dehaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-1153","authenticated-orcid":false,"given":"Dirk","family":"Daelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"75741_CR1","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1039\/D0MD00154F","volume":"11","author":"F Sutanto","year":"2020","unstructured":"Sutanto, F., Konstantinidou, M. & D\u00f6mling, A. Covalent inhibitors: a rational approach to drug discovery. RSC Med. Chem. 11, 876 (2020).","journal-title":"RSC Med. Chem."},{"key":"75741_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/ph16050663","volume":"16","author":"D Schaefer","year":"2023","unstructured":"Schaefer, D. & Cheng, X. Recent advances in covalent drug discovery. Pharmaceuticals 16, 663 (2023).","journal-title":"Pharmaceuticals"},{"key":"75741_CR3","doi-asserted-by":"publisher","first-page":"101615","DOI":"10.1016\/j.rechem.2024.101615","volume":"8","author":"RP Bhole","year":"2024","unstructured":"Bhole, R. P., Joshi, G. O., Kapare, H. S., Chikhale, R. V. & Chaudhari, S. Covalent drug \u2013 an emerging framework for targeted drug development. Results Chem. 8, 101615 (2024).","journal-title":"Results Chem."},{"key":"75741_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejmech.2018.10.010","volume":"160","author":"P \u00c1br\u00e1nyi-Balogh","year":"2018","unstructured":"\u00c1br\u00e1nyi-Balogh, P. et al. A road map for prioritizing warheads for cysteine targeting covalent inhibitors. Eur. J. Med. Chem. 160, 94\u2013107 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"75741_CR5","doi-asserted-by":"publisher","first-page":"7728","DOI":"10.3390\/molecules27227728","volume":"27","author":"F Huang","year":"2022","unstructured":"Huang, F., Han, X., Xiao, X. & Zhou, J. Covalent warheads targeting cysteine residue: the promising approach in drug development. Molecules 27, 7728 (2022).","journal-title":"Molecules"},{"key":"75741_CR6","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","volume":"62","author":"M Gehringer","year":"2019","unstructured":"Gehringer, M. & Laufer, S. A. Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology. J. Med. Chem. 62, 5673\u20135724 (2019).","journal-title":"J. Med. Chem."},{"key":"75741_CR7","doi-asserted-by":"publisher","first-page":"13408","DOI":"10.1002\/anie.201601091","volume":"55","author":"TA Baillie","year":"2016","unstructured":"Baillie, T. A. Targeted covalent inhibitors for drug design. Angew. Chem. Int. Ed. 55, 13408\u201313421 (2016).","journal-title":"Angew. Chem. Int. Ed."},{"key":"75741_CR8","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0092-8674(00)80371-2","volume":"90","author":"M Fornerod","year":"1997","unstructured":"Fornerod, M., Ohno, M., Yoshida, M. & Mattaj, I. W. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90, 1051\u20131060 (1997).","journal-title":"Cell"},{"key":"75741_CR9","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0092-8674(00)80370-0","volume":"90","author":"K Stade","year":"1997","unstructured":"Stade, K., Ford, C. S., Guthrie, C. & Weis, K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 90, 1041\u20131050 (1997).","journal-title":"Cell"},{"key":"75741_CR10","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/36894","volume":"390","author":"M Fukuda","year":"1997","unstructured":"Fukuda, M. et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390, 308\u2013311 (1997).","journal-title":"Nature"},{"key":"75741_CR11","doi-asserted-by":"crossref","unstructured":"Dong, X. et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 458, 1136\u20131141 (2009).","DOI":"10.1038\/nature07975"},{"key":"75741_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1126\/science.1173388","volume":"324","author":"T Monecke","year":"2009","unstructured":"Monecke, T. et al. Crystal structure of the nuclear export receptor CRM1 in complex with snurportin1 and RanGTP. Science 324, 1087\u20131091 (2009).","journal-title":"Science"},{"key":"75741_CR13","doi-asserted-by":"publisher","first-page":"14440","DOI":"10.1073\/pnas.212285299","volume":"99","author":"D Daelemans","year":"2002","unstructured":"Daelemans, D. et al. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc. Natl. Acad. Sci. USA 99, 14440 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75741_CR14","doi-asserted-by":"publisher","first-page":"9487","DOI":"10.1016\/j.bmc.2008.09.051","volume":"16","author":"T Van Neck","year":"2008","unstructured":"Van Neck, T. et al. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure\u2013activity relationship and mechanism of action. Bioorg. Med. Chem. 16, 9487\u20139497 (2008).","journal-title":"Bioorg. Med. Chem."},{"key":"75741_CR15","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","volume":"120","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella, R. et al. Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia. Blood 120, 4621 (2012).","journal-title":"Blood"},{"key":"75741_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/leu.2012.219","volume":"27","author":"J Etchin","year":"2013","unstructured":"Etchin, J. et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 27, 66\u201374 (2013).","journal-title":"Leukemia"},{"key":"75741_CR17","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1073\/pnas.1217203110","volume":"110","author":"Q Sun","year":"2013","unstructured":"Sun, Q. et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc. Natl. Acad. Sci. USA 110, 1303\u20131308 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75741_CR18","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/leu.2016.136","volume":"30","author":"ZA Hing","year":"2016","unstructured":"Hing, Z. A. et al. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. Leukemia 30, 2364\u20132372 (2016).","journal-title":"Leukemia"},{"key":"75741_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-021-01032-2","volume":"14","author":"JS Walker","year":"2021","unstructured":"Walker, J. S. et al. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. J. Hematol. Oncol. 14, 17 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"75741_CR20","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1091\/mbc.E20-04-0233","volume":"31","author":"JM Baumhardt","year":"2020","unstructured":"Baumhardt, J. M. et al. Recognition of nuclear export signals by CRM1 carrying the oncogenic E571K mutation. Mol. Biol. Cell 31, 1879\u20131891 (2020).","journal-title":"Mol. Biol. Cell"},{"key":"75741_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai, Y. T. et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28, 155\u2013165 (2014).","journal-title":"Leukemia"},{"key":"75741_CR22","doi-asserted-by":"crossref","unstructured":"Kwanten, B. et al. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1. Biomed. Pharmacother. 160, 114305 (2023).","DOI":"10.1016\/j.biopha.2023.114305"},{"key":"75741_CR23","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/s41589-025-02058-0","volume":"21","author":"CE Wing","year":"2025","unstructured":"Wing, C. E. et al. SINE compounds activate exportin 1 degradation through an allosteric mechanism. Nat. Chem. Biol. 21, 2002\u20132013 (2025).","journal-title":"Nat. Chem. Biol."},{"key":"75741_CR24","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1091\/mbc.e12-01-0045","volume":"23","author":"D Xu","year":"2012","unstructured":"Xu, D., Grishin, N. V. & Chook, Y. M. A highlights from MBoC selection: NESdb: a database of NES-containing CRM1 cargoes. Mol. Biol. Cell 23, 3673 (2012).","journal-title":"Mol. Biol. Cell"},{"key":"75741_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","volume":"18","author":"AS Azmi","year":"2020","unstructured":"Azmi, A. S., Uddin, M. H. & Mohammad, R. M. The nuclear export protein XPO1\u2014from biology to targeted therapy. Nat. Rev. Clin. Oncol. 18, 152\u2013169 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"75741_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00903-4","volume":"13","author":"NG Azizian","year":"2020","unstructured":"Azizian, N. G. & Li, Y. XPO1-dependent nuclear export as a target for cancer therapy. J. Hematol. Oncol. 13, 1\u20139 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"75741_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41375-021-01483-z","volume":"36","author":"SK Balasubramanian","year":"2022","unstructured":"Balasubramanian, S. K., Azmi, A. S. & Maciejewski, J. Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms. Leukemia 36, 601\u2013612 (2022).","journal-title":"Leukemia"},{"key":"75741_CR28","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-16-1333","volume":"23","author":"Y Chen","year":"2017","unstructured":"Chen, Y. et al. Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer. Clin. Cancer Res. 23, 1552\u20131563 (2017).","journal-title":"Clin. Cancer Res."},{"key":"75741_CR29","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.21037\/tcr-21-1646","volume":"10","author":"L Zhao","year":"2021","unstructured":"Zhao, L. et al. Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis. Transl. Cancer Res. 10, 4664\u20134679 (2021).","journal-title":"Transl. Cancer Res."},{"key":"75741_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1227\/01.NEU.0000348550.47441.4B","volume":"65","author":"A Shen","year":"2009","unstructured":"Shen, A. et al. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 65, 153\u2013159 (2009).","journal-title":"Neurosurgery"},{"key":"75741_CR31","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13045-020-00982-3","volume":"13","author":"M Deng","year":"2020","unstructured":"Deng, M. et al. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J. Hematol. Oncol. 13, 148 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"75741_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","volume":"27","author":"HYJ Fung","year":"2014","unstructured":"Fung, H. Y. J. & Chook, Y. M. Atomic basis of CRM1-cargo recognition, release and inhibition. Semin. Cancer Biol. 27, 52\u201361 (2014).","journal-title":"Semin. Cancer Biol."},{"key":"75741_CR33","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","volume":"79","author":"YY Syed","year":"2019","unstructured":"Syed, Y. Y. Selinexor: first global approval. Drugs 79, 1485\u20131494 (2019).","journal-title":"Drugs"},{"key":"75741_CR34","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/onco.13859","volume":"26","author":"YL Kasamon","year":"2021","unstructured":"Kasamon, Y. L. et al. FDA approval summary: selinexor for relapsed or refractory diffuse large B-cell lymphoma. Oncologist 26, 879 (2021).","journal-title":"Oncologist"},{"key":"75741_CR35","doi-asserted-by":"publisher","first-page":"204062072312194","DOI":"10.1177\/20406207231219442","volume":"15","author":"Q Huang","year":"2024","unstructured":"Huang, Q., Zhao, R., Xu, L., Hao, X. & Tao, S. Treatment of multiple myeloma with selinexor: a review. Ther. Adv. Hematol. 15, 20406207231219440 (2024).","journal-title":"Ther. Adv. Hematol."},{"key":"75741_CR36","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda, N. et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 7, e511\u2013e522 (2020).","journal-title":"Lancet Haematol."},{"key":"75741_CR37","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1200\/JCO.22.02906","volume":"41","author":"I Vergote","year":"2023","unstructured":"Vergote, I. et al. Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. J. Clin. Oncol. 41, 5400\u20135410 (2023).","journal-title":"J. Clin. Oncol."},{"key":"75741_CR38","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1002\/cncr.34820","volume":"129","author":"M Altan","year":"2023","unstructured":"Altan, M. et al. Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. Cancer 129, 2685\u20132693 (2023).","journal-title":"Cancer"},{"key":"75741_CR39","doi-asserted-by":"crossref","unstructured":"Gouda, M. A. et al. A phase Ib study of selinexor in combination with pembrolizumab in patients with metastatic melanoma. J. Immunother. Precis. Oncol. 7, 247\u2013254 (2024).","DOI":"10.36401\/JIPO-24-3"},{"key":"75741_CR40","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki, S. et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 396, 1563\u20131573 (2020).","journal-title":"Lancet"},{"key":"75741_CR41","unstructured":"Study Details | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04421378?cond=glioblastoma&intr=selinexor&rank=2."},{"key":"75741_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/leu.2016.145","volume":"31","author":"J Etchin","year":"2017","unstructured":"Etchin, J. et al. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia 31, 143 (2017).","journal-title":"Leukemia"},{"key":"75741_CR43","doi-asserted-by":"publisher","first-page":"E54","DOI":"10.1002\/ajh.26420","volume":"97","author":"RF Cornell","year":"2022","unstructured":"Cornell, R. F. et al. A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. Am. J. Hematol. 97, E54\u2013E58 (2022).","journal-title":"Am. J. Hematol."},{"key":"75741_CR44","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-16-1580","volume":"23","author":"T Vercruysse","year":"2017","unstructured":"Vercruysse, T. et al. The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia. Clin. Cancer Res. 23, 2528\u20132541 (2017).","journal-title":"Clin. Cancer Res."},{"key":"75741_CR45","first-page":"1560","volume":"7","author":"T Vercruysse","year":"2024","unstructured":"Vercruysse, T. et al. Ibetazol, a novel inhibitor of importin \u03b21-mediated nuclear import. Commun. Biol. 2024 7, 1560 (2024).","journal-title":"Commun. Biol. 2024"},{"key":"75741_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1126\/science.278.5335.141","volume":"278","author":"B Ossareh-Nazari","year":"1997","unstructured":"Ossareh-Nazari, B., Bachelerie, F. & Dargemont, C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science 278, 141\u2013144 (1997).","journal-title":"Science"},{"key":"75741_CR47","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.18632\/oncotarget.6495","volume":"7","author":"ML Crochiere","year":"2016","unstructured":"Crochiere, M. L. et al. A method for quantification of exportin-1 (XPO1) occupancy by selective inhibitor of nuclear export (SINE) compounds. Oncotarget 7, 1863\u20131877 (2016).","journal-title":"Oncotarget"},{"key":"75741_CR48","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1128\/MCB.20.12.4295-4308.2000","volume":"20","author":"M K\u00fcnzler","year":"2000","unstructured":"K\u00fcnzler, M., Gerstberger, T., Stutz, F., Bischoff, F. R. & Hurt, E. Yeast Ran-binding protein 1 (Yrb1) shuttles between the nucleus and cytoplasm and is exported from the nucleus via a CRM1 (XPO1)-dependent pathway. Mol. Cell. Biol. 20, 4295 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"75741_CR49","doi-asserted-by":"publisher","first-page":"68842","DOI":"10.18632\/oncotarget.11995","volume":"7","author":"JE Neggers","year":"2016","unstructured":"Neggers, J. E. et al. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export. Oncotarget 7, 68842 (2016).","journal-title":"Oncotarget"},{"key":"75741_CR50","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.drup.2003.10.004","volume":"6","author":"A O\u2019Brate","year":"2003","unstructured":"O\u2019Brate, A. & Giannakakou, P. The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist Updates 6, 313\u2013322 (2003).","journal-title":"Drug Resist Updates"},{"key":"75741_CR51","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/emboj\/18.6.1660","volume":"18","author":"JM Stommel","year":"1999","unstructured":"Stommel, J. M. et al. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18, 1660 (1999).","journal-title":"EMBO J."},{"key":"75741_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/bjh.12231","volume":"161","author":"J Etchin","year":"2013","unstructured":"Etchin, J. et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br. J. Haematol. 161, 117\u2013127 (2013).","journal-title":"Br. J. Haematol."},{"key":"75741_CR53","doi-asserted-by":"crossref","unstructured":"Liao, J. B. et al. Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer. J. Immunother. Cancer 3, 16 (2015).","DOI":"10.1186\/s40425-015-0060-6"},{"key":"75741_CR54","doi-asserted-by":"crossref","unstructured":"Baert, T. et al. The dark side of ID8-Luc2: Pitfalls for luciferase-tagged murine models for ovarian cancer. J. Immunother. Cancer 3, 57 (2015).","DOI":"10.1186\/s40425-015-0102-0"},{"key":"75741_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-0716-1956-8_1","volume":"2424","author":"AS O\u2019Shea","year":"2022","unstructured":"O\u2019Shea, A. S. Clinical staging of ovarian cancer. Methods Mol. Biol. 2424, 3\u201310 (2022).","journal-title":"Methods Mol. Biol."},{"key":"75741_CR56","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote, I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363, 943\u2013953 (2010).","journal-title":"N. Engl. J. Med."},{"key":"75741_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-00933-8","volume":"22","author":"RD Mahmood","year":"2020","unstructured":"Mahmood, R. D., Morgan, R. D., Edmondson, R. J., Clamp, A. R. & Jayson, G. C. First-line management of advanced high-grade serous ovarian cancer. Curr. Oncol. Rep. 22, 64 (2020).","journal-title":"Curr. Oncol. Rep."},{"key":"75741_CR58","doi-asserted-by":"publisher","first-page":"9112","DOI":"10.1073\/pnas.96.16.9112","volume":"96","author":"N Kudo","year":"1999","unstructured":"Kudo, N. et al. Leptomycin B inactivates CRM1\/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. USA 96, 9112 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75741_CR59","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1182\/blood-2011-01-333138","volume":"118","author":"K Sakakibara","year":"2011","unstructured":"Sakakibara, K. et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1-degrading activity. Blood 118, 3922\u20133931 (2011).","journal-title":"Blood"},{"key":"75741_CR60","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.1021\/acs.jmedchem.0c01675","volume":"64","author":"Y Lei","year":"2021","unstructured":"Lei, Y. et al. Structure-guided design of the first noncovalent small-molecule inhibitor of CRM1. J. Med. Chem. 64, 6596\u20136607 (2021).","journal-title":"J. Med. Chem."},{"key":"75741_CR61","doi-asserted-by":"publisher","first-page":"109305","DOI":"10.1016\/j.bioorg.2025.109305","volume":"168","author":"HS Abulkhair","year":"2026","unstructured":"Abulkhair, H. S. Therapeutic horizons in targeting XPO1 with small inhibitor molecules: recent achievements, synthetic strategies, opportunities, challenges, and future perspectives. Bioorg. Chem. 168, 109305 (2026).","journal-title":"Bioorg. Chem."},{"key":"75741_CR62","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari, A. et al. Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med. 381, 727\u2013738 (2019).","journal-title":"N. Engl. J. Med."},{"key":"75741_CR63","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/blood-2016-11-752840","volume":"130","author":"KR Machlus","year":"2017","unstructured":"Machlus, K. R. et al. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood 130, 1132\u20131143 (2017).","journal-title":"Blood"},{"key":"75741_CR64","doi-asserted-by":"publisher","first-page":"7378","DOI":"10.1038\/sj.onc.1203260","volume":"18","author":"P Smart","year":"1999","unstructured":"Smart, P. et al. Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 18, 7378\u20137386 (1999).","journal-title":"Oncogene"},{"key":"75741_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06525-z","volume":"23","author":"PH Wang","year":"2025","unstructured":"Wang, P. H. et al. Innovative evaluation of selinexor and JQ1 synergy in leukemia therapy via C-MYC inhibition. J. Transl. Med. 23, 520 (2025).","journal-title":"J. Transl. Med."},{"key":"75741_CR66","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2022-160039","volume":"140","author":"H Ali","year":"2022","unstructured":"Ali, H. et al. A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-na\u00efve myelofibrosis. Blood 140, 3986\u20133987 (2022).","journal-title":"Blood"},{"key":"75741_CR67","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/14796694.2025.2461393","volume":"21","author":"J Mascarenhas","year":"2025","unstructured":"Mascarenhas, J. et al. Selinexor plus ruxolitinib in JAK inhibitor treatment-na\u00efve myelofibrosis: SENTRY phase 3 study design. Future Oncol. 21, 807 (2025).","journal-title":"Future Oncol."},{"key":"75741_CR68","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/1078-0432.CCR-21-2225","volume":"28","author":"AB Lassman","year":"2022","unstructured":"Lassman, A. B. et al. A phase II study of the efficacy and safety of oral selinexor in recurrent glioblastoma. Clin. Cancer Res. 28, 452\u2013460 (2022).","journal-title":"Clin. Cancer Res."},{"key":"75741_CR69","first-page":"1","volume":"10","author":"MTC Poon","year":"2020","unstructured":"Poon, M. T. C., Sudlow, C. L. M., Figueroa, J. D. & Brennan, P. M. Longer-term (\u2265\u20092\u00a0years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Sci. Rep. 2020 10, 1\u201310 (2020).","journal-title":"Sci. Rep. 2020"},{"key":"75741_CR70","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/neuonc\/nov297","volume":"18","author":"QT Ostrom","year":"2015","unstructured":"Ostrom, Q. T. et al. American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro. Oncol. 18, i1\u2013i50 (2015).","journal-title":"Neuro. Oncol."},{"key":"75741_CR71","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1002\/cncr.30965","volume":"123","author":"CH Han","year":"2017","unstructured":"Han, C. H. & Batchelor, T. T. Diagnosis and management of primary central nervous system lymphoma. Cancer 123, 4314\u20134324 (2017).","journal-title":"Cancer"},{"key":"75741_CR72","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","volume":"41","author":"L Rong","year":"2022","unstructured":"Rong, L., Li, N. & Zhang, Z. Emerging therapies for glioblastoma: current state and future directions. J. Exp. Clin. Cancer Res. 41, 142 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"75741_CR73","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11060-011-0793-0","volume":"108","author":"FE Bleeker","year":"2012","unstructured":"Bleeker, F. E., Molenaar, R. J. & Leenstra, S. Recent advances in the molecular understanding of glioblastoma. J. Neurooncol. 108, 11\u201327 (2012).","journal-title":"J. Neurooncol."},{"key":"75741_CR74","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s00018-017-2483-3","volume":"74","author":"J Bianco","year":"2017","unstructured":"Bianco, J. et al. On glioblastoma and the search for a cure: where do we stand? Cell. Mol. Life Sci. 74, 2451\u20132466 (2017).","journal-title":"Cell. Mol. Life Sci."},{"key":"75741_CR75","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1021\/acs.jmedchem.8b00147","volume":"62","author":"K Nepali","year":"2019","unstructured":"Nepali, K., Lee, H. Y. & Liou, J. P. Nitro-group-containing drugs. J. Med. Chem. 62, 2851\u20132893 (2019).","journal-title":"J. Med. Chem."},{"key":"75741_CR76","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783\u2013784 (2014).","journal-title":"Nat. Methods"},{"key":"75741_CR77","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"75741_CR78","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/978-1-0716-2337-4_16","volume":"2502","author":"HYJ Fung","year":"2022","unstructured":"Fung, H. Y. J. & Chook, Y. M. Binding affinity measurement of nuclear export signal peptides to their exporter CRM1. Methods Mol. Biol. 2502, 245\u2013256 (2022).","journal-title":"Methods Mol. Biol."},{"key":"75741_CR79","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"75741_CR80","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"75741_CR81","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1107\/S2059798318002425","volume":"74","author":"TI Croll","year":"2018","unstructured":"Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D. Struct. Biol. 74, 519\u2013530 (2018).","journal-title":"Acta Crystallogr. D. Struct. Biol."},{"key":"75741_CR82","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1107\/S2059798317003382","volume":"73","author":"P Emsley","year":"2017","unstructured":"Emsley, P. Tools for ligand validation in Coot. Acta Crystallogr. D. Struct. Biol. 73, 203 (2017).","journal-title":"Acta Crystallogr. D. Struct. Biol."},{"key":"75741_CR83","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","volume":"185","author":"S Banskota","year":"2022","unstructured":"Banskota, S. et al. Engineered virus-like particles for efficient in\u00a0vivo delivery of therapeutic proteins. Cell 185, 250 (2022).","journal-title":"Cell"},{"key":"75741_CR84","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.chembiol.2014.11.015","volume":"22","author":"JE Neggers","year":"2015","unstructured":"Neggers, J. E. et al. Identifying drug-target selectivity of small-molecule CRM1\/XPO1 inhibitors by CRISPR\/Cas9 genome editing. Chem. Biol. 22, 107\u2013116 (2015).","journal-title":"Chem. Biol."},{"key":"75741_CR85","first-page":"1","volume":"8","author":"M Riva","year":"2019","unstructured":"Riva, M. et al. CT-2A neurospheres-derived high-grade glioma in mice: a new model to address tumor stem cells and immunosuppression. Biol. Open 8, 1\u201313 (2019).","journal-title":"Biol. Open"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75741-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:02:29Z","timestamp":1787655749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75741-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75741"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75741-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.D. and W.D. are inventors on the corresponding patent application WO\/2024\/175804 (Nuclear transport modulators). Several authors on this project are employees of KU Leuven, which has a license agreement with Karyopharm Therapeutics Inc. on SINE XPO1 inhibitors. Y.M.C. has a sponsored research agreement with Ignota Labs Ltd. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8940"}}